BRPI1015192A2 - agentes antimicrobianos - Google Patents

agentes antimicrobianos

Info

Publication number
BRPI1015192A2
BRPI1015192A2 BRPI1015192A BRPI1015192A BRPI1015192A2 BR PI1015192 A2 BRPI1015192 A2 BR PI1015192A2 BR PI1015192 A BRPI1015192 A BR PI1015192A BR PI1015192 A BRPI1015192 A BR PI1015192A BR PI1015192 A2 BRPI1015192 A2 BR PI1015192A2
Authority
BR
Brazil
Prior art keywords
relates
present
gram
nucleic acid
furthermore
Prior art date
Application number
BRPI1015192A
Other languages
English (en)
Inventor
Volckaert Guido
Walmagh Maarten
Lavigne Rob
Miller Stefan
Briers Yves
Original Assignee
Katholieke Univ Leuven K U Leuven R&D
Lysando Holding Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Katholieke Univ Leuven K U Leuven R&D, Lysando Holding Ag filed Critical Katholieke Univ Leuven K U Leuven R&D
Publication of BRPI1015192A2 publication Critical patent/BRPI1015192A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)

Abstract

agentes antimicrobianos a presente invenção refere-se a agentes antimicrobianos contra bactérias gramnegativas, em particular a proteínas de fusão compostas de uma enzima que tem a atividade de degradação da parede celular de bactérias gram-negativas e um trecho de peptídeo fundido à enzima no nou cterminal. aiém disso, a presente invenção refere-se às moléculas de ácido nucléico codificando a dita proteína de fusão, vetores compreendendo as ditas moléculas de ácido nucléico e células hospedeiras compreendendo as moléculas de ácido nucléico ou os ditos vetores. além disso, a presente invenção refere-se à dita proteína de fusão para uso como um medicamento, em particular para o tratamento ou prevenção de infecções bacterianas causadas por bactérias gram-negativas, como meios de diagnóstico ou como substância cosmética. a presente invenção também refere-se ao tratamento ou prevenção de contaminação por bactérias gram-negativas de gêneros alimentícios, de equipamentos de processamento de alimentos, de plantas de processamento de alimentos, de superfícies que entram em contato com os alimentos, de dispositivos médicos, de superfícies em hospitais e salas de cirurgia. além disso, a presente invenção refere-se a uma composição farmacêutica compreendendo a dita proteína de fusão.
BRPI1015192A 2009-06-26 2010-06-28 agentes antimicrobianos BRPI1015192A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09163953 2009-06-26
PCT/EP2010/059146 WO2010149792A2 (en) 2009-06-26 2010-06-28 Antimicrobial agents

Publications (1)

Publication Number Publication Date
BRPI1015192A2 true BRPI1015192A2 (pt) 2019-09-17

Family

ID=42799668

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1015192A BRPI1015192A2 (pt) 2009-06-26 2010-06-28 agentes antimicrobianos

Country Status (18)

Country Link
US (3) US8906365B2 (pt)
EP (3) EP2445515B1 (pt)
JP (2) JP6034187B2 (pt)
KR (2) KR101711062B1 (pt)
CN (2) CN102458452B (pt)
AU (3) AU2010264656B2 (pt)
BR (1) BRPI1015192A2 (pt)
CA (1) CA2764131C (pt)
DK (1) DK2445515T3 (pt)
EA (1) EA037202B1 (pt)
ES (1) ES2579806T3 (pt)
HK (1) HK1169311A1 (pt)
IL (2) IL217124A (pt)
MX (2) MX360300B (pt)
PL (1) PL2445515T3 (pt)
SG (1) SG177370A1 (pt)
SI (1) SI2445515T1 (pt)
WO (1) WO2010149792A2 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0815484D0 (en) 2008-08-26 2008-10-01 Univ Leuven Kath Antibacterial agents
JP6034188B2 (ja) 2009-06-26 2016-11-30 ライサンド アクツィエンゲゼルシャフト 抗微生物剤
BRPI1015192A2 (pt) 2009-06-26 2019-09-17 Katholieke Univ Leuven K U Leuven R&D agentes antimicrobianos
AU2010288559B8 (en) * 2009-08-24 2015-08-13 Katholieke Universiteit Leuven, K.U. Leuven R&D New endolysin OBPgpLYS
DK2563916T3 (en) * 2010-04-27 2015-10-05 Lysando Ag METHOD FOR REDUCING biofilms
EP2468856A1 (en) * 2010-12-23 2012-06-27 Lysando Aktiengesellschaft Antimicrobial Agents
MX358864B (es) * 2011-04-12 2018-09-06 Gangagen Inc Polipeptidos antibacterianos quimericos.
US9068204B2 (en) 2013-03-15 2015-06-30 The United States Of America, As Represented By The Secretary Of Agriculture Peptidoglycan hydrolase antimicrobials for eradicating lactobacilli that contaminate and reduce ethanol yields in biofuel fermentation
WO2015070911A1 (en) * 2013-11-14 2015-05-21 Lysando Ag Modified kz144 endolysin sequence
WO2015070912A1 (en) * 2013-11-14 2015-05-21 Lysando Ag Modified el188 endolysin sequence
US10329550B2 (en) 2014-02-14 2019-06-25 Lysando Ag Antimicrobial agents
EP3129044B1 (en) * 2014-04-08 2022-09-07 Lysando AG Peptidoglycan hydrolase for use in the treatment of chronic bacterial infections
CA2953446A1 (en) 2014-06-26 2015-12-30 The Rockefeller University Acinetobacter lysins
CN105734029B (zh) * 2014-12-12 2020-09-25 丰益(上海)生物技术研发中心有限公司 磷脂酶抗菌肽
RU2728682C2 (ru) 2015-09-17 2020-07-31 Контрафект Корпорейшн Применение лизина для восстановления/увеличения антибактериальной активности антибиотиков в присутствии легочного сурфактанта, который ингибирует указанные антибиотики
CN105175509A (zh) * 2015-10-19 2015-12-23 河南科技学院 一种抗菌肽xyz-1及其应用
WO2017151617A1 (en) * 2016-02-29 2017-09-08 Dana-Farber Cancer Institute, Inc. Stapled intracellular-targeting antimicrobial peptides to treat infection
CN109072211B (zh) * 2016-04-28 2023-10-27 莱桑多股份公司 抗沙门氏菌的抗菌剂
WO2018100408A1 (en) * 2016-11-30 2018-06-07 Sasinapas Co.,Ltd. Modified peptides
CN110300760B (zh) * 2016-12-16 2023-10-20 米尼奥大学 新的内溶素
US20180208938A1 (en) * 2017-01-23 2018-07-26 Innate Immunity LLC Compositions and Methods for Protecting Plants Against Bacterial Infections
JP2020515295A (ja) * 2017-04-03 2020-05-28 サシナパス コーポレイション リミテッド 改変されたグラム陰性エンドリシン
JP7305614B2 (ja) 2017-07-19 2023-07-10 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 抗生物質耐性細菌感染症の処置のための安定化抗菌ペプチド
WO2019155002A1 (en) * 2018-02-08 2019-08-15 Institut Pasteur Anti-prevotella bacteriocin methods and compositions
AU2019245369A1 (en) * 2018-03-29 2020-10-29 Contrafect Corporation Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
CN108410840A (zh) * 2018-04-03 2018-08-17 大连理工大学 一种铜绿假单胞菌噬菌体内溶素及其编码基因与应用
JP6979210B2 (ja) * 2018-04-26 2021-12-08 株式会社ニューギン 遊技機
AU2019276252A1 (en) 2018-05-30 2020-11-26 Lysando Ag Novel antimicrobial fusion proteins
JP2021525072A (ja) * 2018-05-30 2021-09-24 ライサンド アーゲー 新規抗微生物タンパク質
EP4118192A1 (en) 2020-03-11 2023-01-18 Telum Therapeutics S.L. New recombinant lysin and its use in the treatment of gram-negative bacterial infections
WO2021185948A1 (en) 2020-03-19 2021-09-23 Micreos Human Health B.V. A stabilized protein of interest
CA3184447A1 (en) * 2020-05-22 2021-11-25 Lysentech Co., Ltd. Novel polypeptide, fusion polypeptide, and antibiotic against gram-negative bacteria comprising same
KR102286544B1 (ko) * 2021-02-10 2021-08-05 주식회사 라이센텍 융합 폴리펩타이드 및 이를 포함하는 그람음성균에 대한 항생제
EP4182334A1 (en) * 2020-07-17 2023-05-24 The University Of Western Australia Compositions and methods for the treatment of cancer
CN111876400B (zh) * 2020-08-06 2022-05-24 昆明理工大学 一种常温裂解酶Sly和编码此酶的多核苷酸
SK289101B6 (sk) * 2020-12-17 2023-08-09 Ústav molekulárnej biológie Slovenskej akadémie vied, verejná výskumná inštitúcia Antimikrobiálny proteín, antimikrobiálny rekombinantný proteín s lytickými vlastnosťami, expresný vektor, spôsob ich prípravy a použitie
US11548917B1 (en) * 2021-11-24 2023-01-10 Intron Biotechnology, Inc. Antibacterial composition effective in treating gram negative bacterial infections and method for preparing the same
CN117534733B (zh) * 2024-01-10 2024-03-29 黑龙江八一农垦大学 抗菌肽cm24、重组基因、乳酸工程菌及其应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE127838T1 (de) 1987-07-06 1995-09-15 Univ Louisiana State Inhibierung von eukaryotischen pathogenen und neoplasmen mit lytischen peptiden.
GB8816693D0 (en) 1988-07-13 1988-08-17 Agricultural & Food Res Viral enzyme & gene
GB2255561B (en) 1991-04-20 1995-06-21 Agricultural & Food Res Lysins from bacteriophages
ATE233817T1 (de) * 1992-08-21 2003-03-15 Univ British Columbia Kationische peptide und verfahren zu deren herstellung
WO1996006532A1 (en) 1994-09-01 1996-03-07 Novo Nordisk A/S A basic protein composition for killing or inhibiting microbial cells
US6503881B2 (en) 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US5997862A (en) 1997-10-31 1999-12-07 New Horizons Diagnostics Corporation Therapeutic treatment of group A streptococcal infections
US6428784B1 (en) 1997-10-31 2002-08-06 New Horizons Diagnostics Corp Vaginal suppository for treating group B Streptococcus infection
US20030113298A1 (en) * 1997-10-31 2003-06-19 Vincent Fischetti Use of bacterial phage associated lysing proteins for the prophylactic and therapeutic treatment of various illnesses
US6288212B1 (en) * 1998-08-28 2001-09-11 The University Of British Columbia Anti-endotoxic, antimicrobial cationic peptides and methods of use therefor
US5993809A (en) 1998-11-18 1999-11-30 Children's Hospital Medical Center Lysozyme fusion proteins in infections
WO2001000855A1 (en) * 1999-06-23 2001-01-04 Ppl Therapeutics (Scotland) Ltd. Fusion proteins incorporating lysozyme
US7338936B2 (en) * 2000-11-28 2008-03-04 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
CA2482995C (en) 2002-04-22 2013-01-29 Dow Global Technologies Inc. Low-cost production of peptides
US7566447B2 (en) * 2003-05-15 2009-07-28 Iogenetics, Llc Biocides
US7935501B2 (en) * 2003-09-11 2011-05-03 Novozymes Pharma Biotec A/S Recombinant production of antimicrobial peptides
WO2005108563A2 (en) 2004-04-19 2005-11-17 University Of Chicago Peptidoglycan-hydrolyzing protein encoded by bacteriophage n4
US20070207209A1 (en) * 2004-08-27 2007-09-06 Murphy Christopher J Trophic factor combinations for nervous system treatment
US7572602B1 (en) 2004-12-03 2009-08-11 The United States Of America As Represented By The Secretary Of Agriculture Nucleic acid encoding endolysin fusion protein
DE102005040347A1 (de) 2005-08-25 2007-03-01 Profos Ag Verfahren und Mittel zur Anreicherung, Entfernung und zum Nachweis von Listerien
US7943128B2 (en) 2006-03-31 2011-05-17 The University Court Of The University Of St Andrews Anti-microbial compositions comprising a cationic peptide and a glycylglycine endopeptidase
DE102006061002A1 (de) 2006-12-22 2008-06-26 Profos Ag Verfahren und Mittel zur Anreicherung, Entfernung und zum Nachweis von gram-positiven Bakterien
CL2008002861A1 (es) * 2007-09-25 2009-03-06 Pastoral Greenhouse Gas Res Limited Polipeptido aislado de m. ruminantium; vector, molecula conjugada y celula huesped que comprenden dicho polipeptido; anticuerpo o fragmento que se une al polipeptido; composicion farmaceutica que comprende la molecula conjugada; metodo para dirigir una celula metanogena para identificacion, aislamiento o inhibicion.
AU2008328584A1 (en) 2007-11-26 2009-06-04 Plant Bioscience Limited Novel polypeptides having endolysin activity and uses thereof
US8481289B2 (en) 2008-07-24 2013-07-09 The United States Of America, As Represented By The Secretary Of Agriculture Triple acting antimicrobials that are refractory to resistance development
EP2157100A1 (en) 2008-08-19 2010-02-24 Profos AG Artificial peptidoglycan lysing enzymes and peptidoglycan binding proteins
GB0815484D0 (en) 2008-08-26 2008-10-01 Univ Leuven Kath Antibacterial agents
CN102395357B (zh) * 2009-02-03 2015-08-26 应用仿生学有限公司 使用聚合的脂蛋白体的纳米结构的膜
WO2010091294A2 (en) 2009-02-05 2010-08-12 The Regents Of The University Of California New targeted antimicrobial moieties
US8383102B2 (en) 2009-05-21 2013-02-26 The United States Of America As Represented By The Secretary Of Agriculture Fusion of peptidoglycan hydrolase enzymes to a protein transduction domain allows eradication of both extracellular and intracellular gram positive pathogens
BRPI1015192A2 (pt) 2009-06-26 2019-09-17 Katholieke Univ Leuven K U Leuven R&D agentes antimicrobianos
JP6034188B2 (ja) 2009-06-26 2016-11-30 ライサンド アクツィエンゲゼルシャフト 抗微生物剤
AU2010288559B8 (en) 2009-08-24 2015-08-13 Katholieke Universiteit Leuven, K.U. Leuven R&D New endolysin OBPgpLYS
DK2563916T3 (en) 2010-04-27 2015-10-05 Lysando Ag METHOD FOR REDUCING biofilms
WO2014001571A1 (en) 2012-06-29 2014-01-03 Lysando Ag Composition for use in mycobacteria diagnosis

Also Published As

Publication number Publication date
JP6034187B2 (ja) 2016-11-30
US20120189606A1 (en) 2012-07-26
EP3058950A3 (en) 2016-10-12
HK1169311A1 (zh) 2013-01-25
EP3058950B1 (en) 2020-03-04
US10137175B2 (en) 2018-11-27
EP3714895A2 (en) 2020-09-30
AU2018201931B2 (en) 2019-08-15
CA2764131A1 (en) 2010-12-29
EP3058950A2 (en) 2016-08-24
AU2018201931A1 (en) 2018-05-31
PL2445515T3 (pl) 2016-10-31
US8906365B2 (en) 2014-12-09
EP3714895A3 (en) 2020-11-25
US20190209663A1 (en) 2019-07-11
EA201270079A1 (ru) 2012-06-29
SG177370A1 (en) 2012-02-28
SI2445515T1 (sl) 2016-08-31
ES2579806T3 (es) 2016-08-16
EA037202B1 (ru) 2021-02-18
JP2017008033A (ja) 2017-01-12
AU2010264656A1 (en) 2011-12-08
CN105440139A (zh) 2016-03-30
MX360300B (es) 2018-10-29
WO2010149792A3 (en) 2011-02-24
AU2010264656B2 (en) 2016-01-21
KR20120095345A (ko) 2012-08-28
IL217124A0 (en) 2012-02-29
EP2445515B1 (en) 2016-04-06
US20150118731A1 (en) 2015-04-30
WO2010149792A2 (en) 2010-12-29
AU2016202296A1 (en) 2016-05-12
IL250938A0 (en) 2017-04-30
JP2012530509A (ja) 2012-12-06
CN105440139B (zh) 2019-08-13
IL217124A (en) 2017-03-30
AU2016202296B2 (en) 2017-12-21
KR101711062B1 (ko) 2017-02-28
US11052137B2 (en) 2021-07-06
KR20170024129A (ko) 2017-03-06
CN102458452A (zh) 2012-05-16
CN102458452B (zh) 2015-12-02
DK2445515T3 (en) 2016-07-04
MX2011013288A (es) 2012-02-28
CA2764131C (en) 2022-05-10
IL250938B (en) 2019-12-31
EP2445515A2 (en) 2012-05-02

Similar Documents

Publication Publication Date Title
BRPI1015192A2 (pt) agentes antimicrobianos
MX2011013453A (es) Agentes antimicrobianos.
BR112013010844A2 (pt) nova endolisina
BR112012026880A2 (pt) método de redução de biofilmes
EA201370145A1 (ru) Антимикробные средства
Adu et al. Microbial biosurfactants in cosmetic and personal skincare pharmaceutical formulations
Mercer et al. Antimicrobial susceptibility testing of antimicrobial peptides to better predict efficacy
WO2010023207A3 (en) Antimicrobial agents
Skowron et al. Human skin microbiome: impact of intrinsic and extrinsic factors on skin microbiota
EA201270322A1 (ru) НОВЫЙ ЭНДОЛИЗИН OBPgpLYS
Fraise et al. The antibacterial activity and stability of acetic acid
Lashua et al. Engineered cationic antimicrobial peptide (eCAP) prevents Pseudomonas aeruginosa biofilm growth on airway epithelial cells
EA201991233A1 (ru) Новый эндолизин
WO2011110655A3 (en) Immunogenic composition or vaccine against gram - negative bacterial, for example neiserial, infection or disease
Zhu et al. Functional synergy of antimicrobial peptides and chlorhexidine acetate against gram-negative/gram-positive bacteria and a fungus in vitro and in vivo
Pace et al. Characterization and antibiofilm activity of mannitol–chitosan-blended paste for local antibiotic delivery system
Zmantar et al. Modulation of drug resistance and biofilm formation of Staphylococcus aureus isolated from the oral cavity of Tunisian children
BR112014027629A2 (pt) misturas de polipeptídeo com atividade antibacteriana
Almaaytah et al. Peptide consensus sequence determination for the enhancement of the antimicrobial activity and selectivity of antimicrobial peptides
BR112015019568A2 (pt) Peptídeo isolado, composição compreendendo o mesmo e uso do mesmo
Draughn et al. Evaluation of a 2-aminoimidazole variant as adjuvant treatment for dermal bacterial infections
Al Tall et al. The design and functional characterization of a novel hybrid antimicrobial peptide from Esculentin-1a and melittin
Hussain et al. In vitro and in vivo study for antibacterial activity of endolysin-HEC gel and mixture gel on acne vulgaris caused by multidrug-resistant Staphylococcus aureus bacteria
Lewies An in vitro evaluation of the antibacterial and anticancer properties of the antimicrobial peptide nisin Z
BR112017020008A2 (pt) peptídeos isolados e seus fragmentos a partir do fibrinogênio para uso como fármacos, particularmente em doenças inflamatórias da pele

Legal Events

Date Code Title Description
B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: LYSANDO HOLDING AG (LI) ; KATHOLIEKE UNIVERSITEIT

Free format text: A FIM DE ATENDER A ALTERACAO DE NOME REQUERIDA ATRAVES DA PETICAO NO 20130039589, DE 09/05/2013, E NECESSARIO APRESENTAR A TRADUCAO JURAMENTADA DO DOCUMENTO, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2542 DE 24-09-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B25E Requested change of name of applicant rejected

Owner name: LYSANDO HOLDING AG (LI) ; KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN RANDD (BE)

Free format text: INDEFERIDO(S) O(S) PEDIDO(S) DE ALTERACAO(OES) DE NOME CONTIDO(S) NA PETICAO 020130039589 DE 09/05/2013 EM VIRTUDE DOS DESPACHOS PUBLICADOS NAS RPI?S 2548 DE 05/11/2019 E 2558 DE 14/01/2020.

B350 Update of information on the portal [chapter 15.35 patent gazette]